BofA reinstated coverage of Akero Therapeutics with a Neutral rating and $30 price target. Investors are “re-warming” to the MASH indication following the FDA’s first approval of a MASH agent, namely Madrigal’s (MDGL) Rezdiffra, after previously having soured on the space in the wake of high-profile clinical and regulatory failures, the analyst tells investors. However, despite efruxermin’s favorable greenspace and “impressive” anti-fibrotic activity, the firm sees several headwinds, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- JPMorgan SMid cap biotech analyst to hold analyst/industry conference call
- Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
- 89bio price target raised to $37 from $29 at Evercore ISI
- Biotech Alert: Searches spiking for these stocks today
